Expression, clinical significance and mechanism of Slit2 in papillary thyroid cancer

Shi,Rong-Liang; Qu,Ning; Liao,Tian; Wang,Yu-Long; Wang,Yu; Sun,Guo-Hua; Ji,Qing-Hai

doi:10.3892/ijo.2016.3412

Expression, clinical significance and mechanism of Slit2 in papillary thyroid cancer

Authors:
- Rong-Liang Shi
- Ning Qu
- Tian Liao
- Yu-Long Wang
- Yu Wang
- Guo-Hua Sun
- Qing-Hai Ji
View Affiliations

Affiliations: Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China
Published online on: March 2, 2016 https://doi.org/10.3892/ijo.2016.3412
Pages: 2055-2062

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Thyroid cancer is a common endocrine malignancy. The last decade has seen exciting progress in understanding thyroid cancer molecular pathogenesis. Several major signaling pathways and related molecular derangements have been elucidated, which represent novel diagnostic and prognostic molecular markers for thyroid cancer. Based on the molecular biology of thyroid cancer, a series of therapeutic targets have been developed, which provide unprecedented opportunities. Thus, histological characterization of subgroups of patients and the correct molecular characterization of patients are thought to be key aspects for future clinical management of these patients. In the present study, we identified Slit2 as a prognostic marker for thyroid cancer oncogenesis and recurrence. Mechanistically, Slit2 regulated Warburg effect in thyroid cancer cells through regulation of HIF1α and HIF1α transcriptional activity. Taken together, our present data uncovered Slit2 as a novel predictive marker for thyroid cancer. The mechanism study indicated that Slit2 regulated the Warburg effect. Additional study on the function of Slit2 in thyroid cancer is required to provide new insights into the potential mechanisms of oncogenesis and recurrence potential of thyroid cancer.

View Figures

View References

1	Faam B, Ghaffari MA, Ghadiri A and Azizi F: Epigenetic modifications in human thyroid cancer. Biomed Rep. 3:3–8. 2015.
2	Kondo T, Ezzat S and Asa SL: Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer. 6:292–306. 2006. View Article : Google Scholar : PubMed/NCBI
3	Patel KN and Shaha AR: Poorly differentiated and anaplastic thyroid cancer. Cancer Control. 13:119–128. 2006.PubMed/NCBI
4	Chen AY, Jemal A and Ward EM: Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer. 115:3801–3807. 2009. View Article : Google Scholar : PubMed/NCBI
5	Davies L and Welch HG: Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 295:2164–2167. 2006. View Article : Google Scholar : PubMed/NCBI
6	Li Y, Nakamura M and Kakudo K: Targeting of the BRAF gene in papillary thyroid carcinoma (Review). Oncol Rep. 22:671–681. 2009.PubMed/NCBI
7	Liu D, Hou J, Hu X, Wang X, Xiao Y, Mou Y and De Leon H: Neuronal chemorepellent Slit2 inhibits vascular smooth muscle cell migration by suppressing small GTPase Rac1 activation. Circ Res. 98:480–489. 2006. View Article : Google Scholar : PubMed/NCBI
8	Wu W, Wong K, Chen J, Jiang Z, Dupuis S, Wu JY and Rao Y: Directional guidance of neuronal migration in the olfactory system by the protein Slit. Nature. 400:331–336. 1999. View Article : Google Scholar : PubMed/NCBI
9	Xu Y, Li WL, Fu L, Gu F and Ma YJ: Slit2/Robo1 signaling in glioma migration and invasion. Neurosci Bull. 26:474–478. 2010. View Article : Google Scholar : PubMed/NCBI
10	Wong K, Ren XR, Huang YZ, Xie Y, Liu G, Saito H, Tang H, Wen L, Brady-Kalnay SM, Mei L, et al: Signal transduction in neuronal migration: Roles of GTPase activating proteins and the small GTPase Cdc42 in the Slit-Robo pathway. Cell. 107:209–221. 2001. View Article : Google Scholar : PubMed/NCBI
11	Wong K, Park HT, Wu JY and Rao Y: Slit proteins: Molecular guidance cues for cells ranging from neurons to leukocytes. Curr Opin Genet Dev. 12:583–591. 2002. View Article : Google Scholar : PubMed/NCBI
12	Qiu H, Zhu J, Yu J, Pu H and Dong R: SLIT2 is epigenetically silenced in ovarian cancers and suppresses growth when activated. Asian Pac J Cancer Prev. 12:791–795. 2011.PubMed/NCBI
13	Dallol A, Morton D, Maher ER and Latif F: SLIT2 axon guidance molecule is frequently inactivated in colorectal cancer and suppresses growth of colorectal carcinoma cells. Cancer Res. 63:1054–1058. 2003.PubMed/NCBI
14	Dallol A, Da Silva NF, Viacava P, Minna JD, Bieche I, Maher ER and Latif F: SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers. Cancer Res. 62:5874–5880. 2002.PubMed/NCBI
15	Shi R, Yang Z, Liu W, Liu B, Xu Z and Zhang Z: Knockdown of Slit2 promotes growth and motility in gastric cancer cells via activation of AKT/β-catenin. Oncol Rep. 31:812–818. 2014.
16	Shi R, Liu W, Liu B, Xu Z, Chen L and Zhang Z: Slit2 expression and its correlation with subcellular localization of β-catenin in gastric cancer. Oncol Rep. 30:1883–1889. 2013.PubMed/NCBI
17	Dallol A, Krex D, Hesson L, Eng C, Maher ER and Latif F: Frequent epigenetic inactivation of the SLIT2 gene in gliomas. Oncogene. 22:4611–4616. 2003. View Article : Google Scholar : PubMed/NCBI
18	Jin J, You H, Yu B, Deng Y, Tang N, Yao G, Shu H, Yang S and Qin W: Epigenetic inactivation of SLIT2 in human hepatocellular carcinomas. Biochem Biophys Res Commun. 379:86–91. 2009. View Article : Google Scholar
19	Chang PH, Hwang-Verslues WW, Chang YC, Chen CC, Hsiao M, Jeng YM, Chang KJ, Lee EY, Shew JY and Lee WH: Activation of Robo1 signaling of breast cancer cells by Slit2 from stromal fibroblast restrains tumorigenesis via blocking PI3K/Akt/β-catenin pathway. Cancer Res. 72:4652–4661. 2012. View Article : Google Scholar : PubMed/NCBI
20	Zhou WJ, Geng ZH, Chi S, Zhang W, Niu XF, Lan SJ, Ma L, Yang X, Wang LJ, Ding YQ, et al: Slit-Robo signaling induces malignant transformation through Hakai-mediated E-cadherin degradation during colorectal epithelial cell carcinogenesis. Cell Res. 21:609–626. 2011. View Article : Google Scholar : PubMed/NCBI
21	Muñoz-Pinedo C, El Mjiyad N and Ricci JE: Cancer metabolism: Current perspectives and future directions. Cell Death Dis. 3:e2482012. View Article : Google Scholar : PubMed/NCBI
22	Dang CV: Links between metabolism and cancer. Genes Dev. 26:877–890. 2012. View Article : Google Scholar : PubMed/NCBI
23	Deberardinis RJ, Sayed N, Ditsworth D and Thompson CB: Brick by brick: Metabolism and tumor cell growth. Curr Opin Genet Dev. 18:54–61. 2008. View Article : Google Scholar : PubMed/NCBI
24	Cairns RA, Harris IS and Mak TW: Regulation of cancer cell metabolism. Nat Rev Cancer. 11:85–95. 2011. View Article : Google Scholar : PubMed/NCBI
25	Meijer TW, Kaanders JH, Span PN and Bussink J: Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin Cancer Res. 18:5585–5594. 2012. View Article : Google Scholar : PubMed/NCBI
26	Denko NC: Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer. 8:705–713. 2008. View Article : Google Scholar
27	Keith B, Johnson RS and Simon MC: HIF1α and HIF2α: Sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 12:9–22. 2011.PubMed/NCBI
28	Pereira KM, Chaves FN, Viana TS, Carvalho FS, Costa FW, Alves AP and Sousa FB: Oxygen metabolism in oral cancer: HIF and GLUTs (Review). Oncol Lett. 6:311–316. 2013.PubMed/NCBI
29	Bertout JA, Patel SA and Simon MC: The impact of O2 availability on human cancer. Nat Rev Cancer. 8:967–975. 2008. View Article : Google Scholar : PubMed/NCBI
30	Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM, Royer RE, Vander Jagt DL, Semenza GL and Dang CV: Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci USA. 107:2037–2042. 2010. View Article : Google Scholar : PubMed/NCBI
31	Vaupel P, Mayer A and Höckel M: Tumor hypoxia and malignant progression. Methods Enzymol. 381:335–354. 2004. View Article : Google Scholar : PubMed/NCBI
32	Semenza GL: Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene. 29:625–634. 2010. View Article : Google Scholar :